Shield Therapeutics (STX) Q3 2026 TU earnings summary

Executive summary

• Q3 net revenue increased 2% QoQ excluding Q2 milestone revenue; commercial prescriptions and net revenue per prescription improved.

• Full U.S. commercial responsibility began October 1, improving revenue retention and gross-margin economics; FY 2026 guidance shifted to a single-digit US$ million operating loss.

Financial highlights

• Q3 net revenue was $11.5m versus $11.9m in Q2, which included a $0.6m milestone; excluding milestones, revenue rose 2% QoQ from $11.3m.

• U.S. ACCRUFeR revenue rose 5% QoQ to $10.8m from $10.3m; net revenue per prescription increased 4% to $217 from $208.

• Ex-U.S. revenue was $0.7m versus $1.0m in Q2; 9M 2026 revenue was $41.9m, including a milestone.

• Quarter-end cash was $6.8m, down $1.5m from June 30; cash use was mainly attributed to working capital, and no credit-facility draw was made.

Outlook and guidance

• FY 2026 operating profitability is no longer expected; guidance anticipates a single-digit US$ million operating loss, primarily reflecting increased commercial costs after full U.S. control.

• Q4 is expected to be the first quarter with the lower Viatris royalty rate and full U.S. economics; commercial growth and cost discipline remain priorities.

• FY 2027 guidance is due with the Q4 and FY 2026 update; sustainable profitability as soon as possible remains the Board’s priority.

• Korea and China could launch in 2027; China timing could shift to 2028 depending on regulatory approval, reimbursement filings and achievable pricing.